Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Immtech's DB289 placed on hold

IMM fell $2.97 (51%) to $2.88 after FDA placed the company's

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE